A Study of LY4213663
Phase 1
134
about 2.3 years
18–75
9 sites in AL, AZ, FL +1
About this study
Researchers are testing a treatment called LY4213663 in people who are healthy and those with rheumatoid arthritis (RA). The trial will last about 33 weeks, excluding the time needed to be screened for eligibility. Blood tests will be done to see how well the body processes the drug and what effects it has.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LY4213663
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4213663, Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4213663
Immune